RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

On March 22, 2018 Rasna Therapeutics, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the“Meeting”). At the Meeting, the Company’s stockholders (i) re-elected Kunwar Shailubhai, Riccardo Dalla-Favera, James Mervis, John P. Brancaccio, Alessandro Padova, and John Alex Martin as directors of the Company’s Board and (ii) ratified the appointment of Marcum LLP as the Company’s independent auditors for the fiscal year ending September 30, 2018.

As of February 16, 2018, the record date for the Meeting, there were 68,908,003shares of our common stock outstanding, which was sufficient to constitute a quorum.

Set forth below are the final voting results for each of the proposals:

Proposal No. 1- Election of Directors

Proposal No. 2 – Ratification of the appointment of Marcum LLP as the Company’s independent auditors for the fiscal year ending September 30, 2018.

.

About RASNA THERAPEUTICS, INC. (OTCMKTS:RASP)

Rasna Therapeutics, Inc., formerly Active With Me Inc., creates online resources that offer travelers information on activity-based travel. The Company’s Website focuses on offering third-party content and information to visitors in their activity of choice. The Company’s Website also focuses on offering links to clubs and organizations. The Company is in development-stage. Rasna DE is the subsidiary of the Company. Rasna DE is engaged in modulating the molecular targets nucleophosmin gene (NPM1) and lysine (K)-specific demethylase 1A (LSD1), which are implicated in the disease progression of leukemia and lymphoma. The Company focuses on performing preclinical research on NPM1 and LSD1. As of June 30, 2016, the Company had not generated any revenues.